```
16/30 - (C) Derwent
AN - 90-181364 [24]
XA - C90-078781
                  N90-140904
                  ***Vascular*** ***endothelial*** cell growth factor - is obtd. by
             condensing serum-free cultured supernatant soln. of human diploid fibroblast cells and purifying
                 BO4 D16 P34
(TORA ) TORAY IND INC
(AJIN ) AJINOMOTO KK
DC
PA
NP
                 J02117698 A 900502 DW9024
88JP-271389 881027
88JP-271389 881027
PN
PR
AP
                  A61K-037/24 A61K-049/00 A61L-027/00 C07K-015/12 C12P-021/02
            C12R-001/91
                 J02117698 Purified ***vascular*** ***endothelial*** cell growth
             factor is obtd. by condensing serum-free cultured supernatant soln. of
             human diploid fibroblast cells via ultrafiltration and purifying
            human diploid fibroblast cells via ultrafiltration and purifying condensed soln. via heparin cephallose affinity chromatography and reverse phase HPLC. Factors show growth promoting activity to ****vascular*** ****endothelial*** cells and show no activity to Balb/3T3 and human diploid fibroblast-cells. Factors do not inhibit combining of 125I-FGF to HepG2 cell surface FGF receptors.

USE/ADVANTAGE — Endothelial cell growth factor (ECGF) are useful for treatments for burn and cardiovascular disorders. Also, ECGF are useful material for treatments and diagnosis of malignant tumour, retinitis, chronic rheumatism, etc.. Also ECGF are hingly purified and obtd. by method of higher productivity and stability over conventional
            obtd. by method of higher productivity and stability over conventional methods. (4pp Dwg.No.0/0)
```

·.

```
22/30 - (C) Derwent
                      89-088700 [12]
C89-039214
 AN -
                       ***Vascular*** ***endothelial*** cell growth factor protein - used
                  for treatment of e.g. wound and cardio angiopathy and for diagnosing
                 e.g. tumours, etc.
BO4 D16
DC
PA
NP
PN
PR
AP
IC
                        (TORA ) TORAY IND INC
                       J01038100 A 890208 DW8912
                      87JP-193303 870731
                      87JP-193303 870731
A61K-037/02 C07K-015/06 C12P-021/00 C12R-001/91
                J01038100 ***Vascular*** ****endothelial*** cell growth factor (ECGF) protein has a M.W. under the non-redn condition of 38000-48000. ECGF is inactivated by reducing treatment. The isoelectric point is 8.5-9.0.
               8.5-9.0.

USE/ADVANTAGE - ECGF is useful for treatment of e.g. wound and cardio-angiopathy, and for diagnosis of e.g. tumours, retinopathy, chronic rheumatism. ECGF can be efficiently and safely obtd.

In an example, human diploid fibroblast is grown in Eagle MEM medium including 5% bovine serum, and grown in a medium including no serum. The obtd supernatant soln is concn, and ECGF active ingredients are absorbed in a column, eluated and absorbed TSK gel Ether-5PW in the presence of ammonium acetate. The obtd fraction is eluted and subjected to SDS-PAGE (contg no reducing agent) to obtain M.W. of 3SOOO-48000. when a reducing agent is present, ECGF activity is not detected. By PAGE isoelectric method, pI can be obtd 8.5-9.0. (4pp Dwo.No.0/3)
```

Dwg. No. 0/3)